Sterigenics International LLC Changes Name to Sotera Health LLC
Sterigenics International LLC (the “Company”) announced today that it has changed its parent company name to Sotera Health LLC. Its three operating companies – Nelson Labs™, Nordion® and Sterigenics® – will continue to maintain their current names. The new parent company name signals a more integrated and holistic customer value proposition as it combines the offerings of three best-in-class companies to better serve customers with a more comprehensive offering of mission-critical services.
The name Sotera was inspired by the Greek goddess of safety, Soteria, and reflects the Company’s unwavering commitment to global health. As the global leader in mission-critical services to ensure the safety of healthcare, Sotera Health has 62 facilities in 13 countries and provides rigorous lab services, comprehensive sterilization solutions and a reliable global supply of radioisotopes to the medical device, pharmaceutical, tissue and food industries. The company touches the lives of more than 180 million people around the world each year and serves over 6,000 global customers, including 75% of the top 100 medical device manufacturers.
“Safeguarding Global Health™ is the cornerstone of our new brand and guides us in what we do each and every day,” said Michael B. Petras Jr., CEO of Sotera Health. “It speaks to the breadth of our business and our ability to partner with our customers across their entire product-development lifecycle.”
The new brand was developed after an extensive process of in-depth engagement with customers, suppliers, employees and Company leadership. The companies and services under the Sotera Health umbrella are:
- Nelson Labs is the industry-leading provider of global lab testing and expert consulting services. Nelson Labs performs over 400 rigorous microbiological and analytical laboratory tests across the medical device, pharmaceutical and tissue industries. The company is regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues. Most recently, the company announced the acquisition of Toxikon Europe, which, in combination with Nelson Labs, will create the leading global extractables and leachables lab testing platform.
- Nordion is the leading global provider of mission-critical radioisotopes used for the prevention, diagnosis and treatment of disease. Nordion ensures the reliable supply of Cobalt-60, the primary input to the gamma sterilization process, to the leaders in healthcare, including sister company Sterigenics.
- Sterigenics is the leading global provider of comprehensive sterilization solutions that eliminate potential health threats, using the most advanced and reliable medical sterilization techniques available. Sterigenics has deep expertise across Gamma, Ethylene Oxide (EO), Electron Beam (E-beam) and X-ray sterilization.
“Our new brand underscores the customers’ recognition of our more expansive partnership as they innovate in an ever-changing and increasingly regulated healthcare world,” added Petras. “We look forward to providing them with the same best-in-class service, quality and expertise in a more integrated service offering.”
About Sotera Health:
Sotera Health LLC, along with its business entities, is the world’s leading, fully integrated protector of global health. With over 500 years of combined scientific expertise, the company ensures the safety of healthcare by providing mission-critical services to the medical device, pharmaceutical, tissue and food industries. Sotera Health operates more than 62 facilities in 13 countries. The company has over 2,800 employees globally and touches the lives of more than 180 million people around the world each year. Sotera Health serves more than 6,000 customers worldwide including 75 of the top 100 medical device manufacturers.
Sotera Health goes to market through its three best-in-class companies – Nelson Labs™, Nordion® and Sterigenics® - with the mission of ensuring the safety of healthcare each and every day. Nelson Labs, along with recently acquired Toxikon Europe, offers microbiological and analytical testing and consultancy to assist customers in developing and maintaining sterilization solutions in medical devices, tissue/implantable products, and the pharmaceutical and biologics fields. Nordion is the world’s largest provider of Cobalt-60 used in the gamma sterilization process as well as medical isotopes used in the diagnosis and treatment of various diseases and cancers. Sterigenics provides comprehensive contract sterilization and ionization solutions for the medical device, pharmaceutical, food safety and high-performance materials industries.
Sotera Health LLC is owned by private equity firms Warburg Pincus and GTCR. Learn more about Sotera Health at soterahealth.com, about Nelson Labs at nelsonlabs.com, about Nordion at nordion.com and about Sterigenics at sterigenics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171107006174/en/
Contact information
Dix & Eaton
Amy McGahan, 216-241-3027
amcgahan@dix-eaton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9% 15.6% -241 bps -306 bps Net income attributable to SLB - GAAP basis $797 $1,095 $1,068 -27% -25% Diluted EPS - GAAP basis $0.58 $0.77 $0.74 -25% -22% Adjusted EBITDA* $2,020 $2,382 $2,057 -15% -2% Adjusted EBITDA margin* 23.8% 25.7% 23.6% -186 bps 18 bps Pretax segment operating income* $1,556 $1,918 $1,649 -19% -6% Pretax segment operating margin* 18.3% 20.7% 18.9% -232 bps -60 bps Net income attributable to SLB, excluding charges &
Corona, The World’s Most Valuable Beer Brand 1 , Announces Its 100-Year Anniversary with Global Celebration25.4.2025 11:00:00 EEST | Press release
Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side. “For 100 years, Corona has
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 10:28:00 EEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom